KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Finished Goods (2020 - 2023)

Teladoc Health's Finished Goods history spans 4 years, with the latest figure at $26.3 million for Q1 2023.

  • On a quarterly basis, Finished Goods fell 41.82% to $26.3 million in Q1 2023 year-over-year; TTM through Mar 2023 was $26.3 million, a 41.82% decrease, with the full-year FY2022 number at $32.0 million, down 34.93% from a year prior.
  • Finished Goods hit $26.3 million in Q1 2023 for Teladoc Health, down from $32.0 million in the prior quarter.
  • Over the last five years, Finished Goods for TDOC hit a ceiling of $49.1 million in Q4 2021 and a floor of $26.3 million in Q1 2023.
  • Historically, Finished Goods has averaged $37.4 million across 4 years, with a median of $36.1 million in 2020.
  • Biggest five-year swings in Finished Goods: soared 38.53% in 2021 and later plummeted 41.82% in 2023.
  • Tracing TDOC's Finished Goods over 4 years: stood at $35.5 million in 2020, then soared by 38.53% to $49.1 million in 2021, then tumbled by 34.93% to $32.0 million in 2022, then decreased by 17.63% to $26.3 million in 2023.
  • Business Quant data shows Finished Goods for TDOC at $26.3 million in Q1 2023, $32.0 million in Q4 2022, and $36.8 million in Q3 2022.